Anti White Powder Toremifene Citrate Anabolic Hormones Anti Estrogen Steroids
سترات التشريفين/فارستون مواصفات:
| Toremifene Citrate Name | Toremifene citrate |
| Toremifene Citrate Synonyms | FC 1157A; فارستون; NK 622; مجلس الأمن القومي 613680 |
| Toremifene Citrate CAS | 89778-27-8 |
| Toremifene Citrate Assay | 99% دقيقة |
| Toremifene Citrate PSA | 144.60000 |
| Toremifene Citrate LogP | 4.96650 |
| Toremifene Citrate Appearance & Physical State | White or almost white powder |
| Toremifene Citrate Density | 1.045ز/سم3 |
| Toremifene Citrate Melting Point | 158-164درجة مئوية |
| Toremifene Citrate Boiling Point | 535.1ºC at 760 مم زئبق |
| Toremifene Citrate Flash Point | 277.4درجة مئوية |
| Toremifene Citrate Refractive Index | 1.416-1.418 |
| Toremifene Citrate Storage Condition | -20ºC Freezer |
| Toremifene Citrate Half Life | 5 أيام |
| Toremifene Citrate Detection Time | المجهول |
| Toremifene Citrate Anabolic Rating | N/A |
| Toremifene Citrate Androgenic Rating | N/A |
سترات التشريفين/فارستون الوصف:
Toremifene (also known under its brand and trade name of Fareston) is a member of a category, family, and class of drugs that are known as SERMs (Selective Estrogen Receptor Modulators). SERMs fall under an even broader category of drugs that are known as anti-estrogens, and the cousin family of SERMs (that also fall under anti-estrogens) are aromatase inhibitors, commonly abbreviated as AIs.
Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene. SERMs include compounds such as Toremifene, نولفاديك(Tamoxifen), and Clomid (كلوميدين سيترات). Aromatase inhibitors (AIs) include compounds such as Arimidex (أناستروزولي), اروماسين (إكسميستان), and Letrozole (فيمارا).
سترات التشريفين/فارستون الفوائد:
- It is clinically proven. In a number of important measurements of a drug’s effectiveness in treating metastatic ER+ breast cancer in postmenopausal women, Fareston worked just as well as tamoxifen1-4
- May provide the continued benefits of endocrine therapy. Fareston may offer you the continued benefits of endocrine therapy if you cannot tolerate or are otherwise unable to take other endocrine therapies1-6
- Fareston may be an effective alternative for patients who have stopped taking other endocrine therapies because of joint pain1-4,6
- Is available and accessible. Fareston is widely available on commercial and Medicare Part D formularies and is covered by most commercial and Medicare insurance plans.
